A New Structural Model of Apolipoprotein B100 Based on Computational Modeling and Cross Linking
Overview
Chemistry
Molecular Biology
Authors
Affiliations
ApoB-100 is a member of a large lipid transfer protein superfamily and is one of the main apolipoproteins found on low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles. Despite its clinical significance for the development of cardiovascular disease, there is limited information on apoB-100 structure. We have developed a novel method based on the "divide and conquer" algorithm, using PSIPRED software, by dividing apoB-100 into five subunits and 11 domains. Models of each domain were prepared using I-TASSER, DEMO, RoseTTAFold, Phyre2, and MODELLER. Subsequently, we used disuccinimidyl sulfoxide (DSSO), a new mass spectrometry cleavable cross-linker, and the known position of disulfide bonds to experimentally validate each model. We obtained 65 unique DSSO cross-links, of which 87.5% were within a 26 Å threshold in the final model. We also evaluated the positions of cysteine residues involved in the eight known disulfide bonds in apoB-100, and each pair was measured within the expected 5.6 Å constraint. Finally, multiple domains were combined by applying constraints based on detected long-range DSSO cross-links to generate five subunits, which were subsequently merged to achieve an uninterrupted architecture for apoB-100 around a lipoprotein particle. Moreover, the dynamics of apoB-100 during particle size transitions was examined by comparing VLDL and LDL computational models and using experimental cross-linking data. In addition, the proposed model of receptor ligand binding of apoB-100 provides new insights into some of its functions.
Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor.
Reimund M, Dearborn A, Graziano G, Lei H, Ciancone A, Kumar A Nature. 2024; 638(8051):829-835.
PMID: 39663455 DOI: 10.1038/s41586-024-08223-0.
The structure of apolipoprotein B100 from human low-density lipoprotein.
Berndsen Z, Cassidy C Nature. 2024; 638(8051):836-843.
PMID: 39662503 PMC: 11839476. DOI: 10.1038/s41586-024-08467-w.
Danner R, Prochniak L, Pereckas M, Rouse J, Wahhab A, Hackner L J Infect Dis. 2024; 230(Supplement_1):S27-S39.
PMID: 39140726 PMC: 11322890. DOI: 10.1093/infdis/jiae324.
Peptidomimetics for CVD screened via TRADD-TRAF2 complex interface assessments.
Manikandan A, Jeevitha S, Vusa L In Silico Pharmacol. 2023; 11(1):28.
PMID: 37899969 PMC: 10611682. DOI: 10.1007/s40203-023-00166-0.
Molk N, Bitenc M, Urlep D, Zerjav Tansek M, Bertok S, Trebusak Podkrajsek K Front Med (Lausanne). 2023; 10:1106441.
PMID: 37384046 PMC: 10293746. DOI: 10.3389/fmed.2023.1106441.